RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SK Biopharmaceuticals Co Stock

SK Biopharmaceuticals Co Market capitalization 2024

SK Biopharmaceuticals Co Market capitalization

8.1 T KRW

Ticker

326030.KS

ISIN

KR7326030004

In 2024, SK Biopharmaceuticals Co's market cap stood at 8.1 T KRW, a 24.73% increase from the 6.49 T KRW market cap in the previous year.

The SK Biopharmaceuticals Co Market capitalization history

YEARMarket Capitalization (undefined KRW)
20236.1
20226.03
20219.14
202012.41
2019-
2018-
2017-

SK Biopharmaceuticals Co Aktienanalyse

What does SK Biopharmaceuticals Co do?

SK Biopharmaceuticals Co Ltd is a leading bio-pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for central nervous system (CNS) disorders. The company is headquartered in South Korea and has been listed on the Korean Stock Exchange since 2014. The history of SK Biopharmaceuticals dates back to 1998 when it was established as a joint venture between SK Group and Hanmi Pharmaceutical. SK Biopharmaceuticals works closely with its parent companies, utilizing their extensive experience and infrastructure in research and development, production, and marketing. The business model of SK Biopharmaceuticals is based on creating value through research and development of drugs for the global market. Within this framework, the company develops innovative bio-pharmaceutical solutions for a range of therapeutic areas, particularly CNS disorders. SK Biopharmaceuticals strives to establish a strong presence in the global bio-pharmaceutical market through partnerships and strategic alliances with other companies. SK Biopharmaceuticals is organized into various divisions, including research and development, production, sales, and marketing. Each of these divisions is tailored to meet the needs of customers and patients to ensure optimal access to medications. The company has various products with different indications on the market worldwide, including the anticonvulsant Brivaracetam, which is approved for the treatment of epilepsy. Brivaracetam is a fast-acting, highly selective, and potent anticonvulsant that demonstrates significant reduction in seizure frequency in patients with epilepsy. SK Biopharmaceuticals continuously works to expand its product portfolio and develop innovative solutions for the treatment of neurological disorders. In addition to drug development for the global market, SK Biopharmaceuticals is also active in the field of biotechnology. The company is committed to harnessing the latest advancements in biotechnology and genomics to support the discovery, development, and commercialization of medications. SK Biopharmaceuticals has established itself as a leading company in the bio-pharmaceutical industry. The company is dedicated to excellence in research, development, and marketing of innovative solutions for the treatment of neurological disorders. With a strong global presence and a dedicated workforce, SK Biopharmaceuticals is well-positioned to further expand its position as a pioneer in the bio-pharmaceutical industry. SK Biopharmaceuticals Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring SK Biopharmaceuticals Co's Market Capitalization

SK Biopharmaceuticals Co's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of SK Biopharmaceuticals Co's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

SK Biopharmaceuticals Co's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in SK Biopharmaceuticals Co’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about SK Biopharmaceuticals Co stock

What is the current SK Biopharmaceuticals Co market capitalization?

The current market capitalization of SK Biopharmaceuticals Co is 8.1 T KRW.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like SK Biopharmaceuticals Co.

How has the market capitalization of SK Biopharmaceuticals Co developed in recent years?

The market capitalization of SK Biopharmaceuticals Co has increased/decreased by 24.73% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of SK Biopharmaceuticals Co?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of SK Biopharmaceuticals Co?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of SK Biopharmaceuticals Co have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does SK Biopharmaceuticals Co pay?

Over the past 12 months, SK Biopharmaceuticals Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SK Biopharmaceuticals Co is expected to pay a dividend of 0 KRW.

What is the dividend yield of SK Biopharmaceuticals Co?

The current dividend yield of SK Biopharmaceuticals Co is .

When does SK Biopharmaceuticals Co pay dividends?

SK Biopharmaceuticals Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SK Biopharmaceuticals Co?

SK Biopharmaceuticals Co paid dividends every year for the past 0 years.

What is the dividend of SK Biopharmaceuticals Co?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is SK Biopharmaceuticals Co located?

SK Biopharmaceuticals Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von SK Biopharmaceuticals Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SK Biopharmaceuticals Co from 9/29/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did SK Biopharmaceuticals Co pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of SK Biopharmaceuticals Co in the year 2023?

In the year 2023, SK Biopharmaceuticals Co distributed 0 KRW as dividends.

In which currency does SK Biopharmaceuticals Co pay out the dividend?

The dividends of SK Biopharmaceuticals Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SK Biopharmaceuticals Co

Our stock analysis for SK Biopharmaceuticals Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SK Biopharmaceuticals Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.